Companies: 10,795·Total market cap: $144.5T
Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc.

AMRXNASDAQHealthcare● Active
$13.75
+$0.23(+1.70%)
Market Cap$4.4B
P/E Ratio
52W High$15.42
52W Low$7.07
SEC Filings

Amneal Pharmaceuticals, Inc. (AMRX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001723128 · AMRX · NASDAQ · as of Jun 8, 2026

Filing snapshot

664
Total Filings
4
Latest Form
2026-05-12
Most Recent
2018
Filing Since

Source: SEC EDGAR (data.sec.gov) · CIK 0001723128 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-02-27
Fiscal Year End
Feb 27, 2026
Accession No.
0001723128-26-000011
Primary Document
amrx-20251231.htm
Source: data.sec.gov · CIK 0001723128 · Accession 0001723128-26-000011

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
8-KCurrent Report
8-K
2026-05-07Material Event
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

SEC Filing History

Hide Form 4 / 144
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
SCHEDULE 13GSCHEDULE 13G
SCHEDULE 13G
2026-04-27
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-23
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-22
View
8-KCurrent Report
8-K
2026-04-22
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-26
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-03-26
View
DEFA14AProxy Statement (Additional)
DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS
2026-03-25
View
Showing 1–15 of 329 filingsForm 4 / 144 hidden· 664 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001723128  |  Exchange: NASDAQ · Healthcare

Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) has submitted 664 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2018. As a Healthcare sector company with CIK 0001723128, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Amneal Pharmaceuticals, Inc.'s most comprehensive regulatory disclosure. The most recent Amneal Pharmaceuticals, Inc. 10-K was filed on 2026-02-27 for fiscal year ending 2026. Historical AMRX 10-K annual reports are available from 2017 through 2026.

Investors researching Amneal Pharmaceuticals, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08

Frequently Asked Questions

AMRX SEC Filings · 8 questions

Amneal Pharmaceuticals, Inc. (AMRX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 664 filings and access original documents at no cost. Amneal Pharmaceuticals, Inc.'s CIK is 0001723128.

AMRX SEC filingsAmneal Pharmaceuticals, Inc. SEC documentsfind AMRX 10-K